KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Invested Capital: 2018-2025

Historic Invested Capital for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $477.1 million.

  • Castle Biosciences' Invested Capital rose 5.77% to $477.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $477.1 million, marking a year-over-year increase of 5.77%. This contributed to the annual value of $465.9 million for FY2024, which is 19.06% up from last year.
  • Castle Biosciences' Invested Capital amounted to $477.1 million in Q3 2025, which was up 2.51% from $465.4 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Invested Capital registered a high of $477.1 million during Q3 2025, and its lowest value of $378.8 million during Q2 2023.
  • For the 3-year period, Castle Biosciences' Invested Capital averaged around $427.0 million, with its median value being $433.9 million (2024).
  • In the last 5 years, Castle Biosciences' Invested Capital soared by 269.52% in 2021 and then fell by 10.17% in 2023.
  • Castle Biosciences' Invested Capital (Quarterly) stood at $411.7 million in 2021, then dropped by 3.06% to $399.1 million in 2022, then decreased by 1.97% to $391.3 million in 2023, then climbed by 19.06% to $465.9 million in 2024, then climbed by 5.77% to $477.1 million in 2025.
  • Its last three reported values are $477.1 million in Q3 2025, $465.4 million for Q2 2025, and $450.3 million during Q1 2025.